Tumour dormancy: findings and hypotheses from clinical research on breast cancer.

Breast cancer metastatic development is commonly considered as resulting from continuous tumour growth from tumour seeding until clinical recurrence is documented. Continuous growth model inferences, however, fail to explain clinical findings concerning local recurrences, as well as the time-distribution of first treatment failure and mortality for patients undergoing mastectomy. The tumour dormancy hypothesis is considered to provide a more reasonable description of the natural history of breast cancer, while primary tumour removal is believed to be a potential perturbing factor for metastasis development. A new model of the natural history of operable breast cancer, incorporating tumour dormancy and starting signals from surgery for micrometastatic growth is proposed.

[1]  M. von Knebel Doeberitz,et al.  Detection and clinical relevance of micrometastatic cancer cells , 2000, Current opinion in oncology.

[2]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[3]  C. Fearns,et al.  Unusual growth characteristics of human melanoma xenografts in the nude mouse: a model for desmoplasia, dormancy and progression. , 1992, British Journal of Cancer.

[4]  W. Hrushesky,et al.  Menstrual Timing of Breast Cancer Surgery 12 , 1998 .

[5]  G. Hortobagyi High-dose chemotherapy for primary breast cancer: facts versus anecdotes. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Izbicki,et al.  Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. , 1993, Journal of the National Cancer Institute.

[7]  J. Birkbeck Meat and cancer , 1991, The Lancet.

[8]  R. Scheuermann,et al.  Cancer dormancy: Opportunities for new therapeutic approaches , 1997, Nature Medicine.

[9]  D J Ferguson,et al.  Dormancy of mammary carcinoma after mastectomy. , 1999, Journal of the National Cancer Institute.

[10]  E. Copson,et al.  Herceptin (trastuzamab) in advanced breast cancer. , 2000, Cancer treatment reviews.

[11]  R. Demicheli,et al.  Does surgery modify growth kinetics of breast cancer micrometastases? , 2001, British Journal of Cancer.

[12]  T. P. Pretlow,et al.  Development of micrometastases: earliest events detected with bacterial lacZ gene-tagged tumor cells. , 1990, Journal of the National Cancer Institute.

[13]  S. Gruber,et al.  MENSTRUAL INFLUENCE ON SURGICAL CURE OF BREAST CANCER , 1989, The Lancet.

[14]  I. Fidler,et al.  The biology of tumor metastasis. , 1989, Seminars in oncology.

[15]  A. Schätzlein,et al.  Tumour vasculature as a target for anticancer therapy. , 2000, Cancer treatment reviews.

[16]  G. Nicolson,et al.  Molecular mechanisms of cancer metastasis: tumor and host properties and the role of oncogenes and suppressor genes , 1991, Current opinion in oncology.

[17]  J. Crowe,et al.  Local-regional breast cancer recurrence following mastectomy. , 1991, Archives of surgery.

[18]  P. Drew,et al.  Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery? , 1998, British Journal of Cancer.

[19]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[20]  N Gunduz,et al.  Presence of a growth-stimulating factor in serum following primary tumor removal in mice. , 1989, Cancer research.

[21]  B. Lord,et al.  Growth Kinetics of Tumours , 1978, British Journal of Cancer.

[22]  K. Woo,et al.  Growth kinetics of small cell carcinoma of the lung. , 1981, European journal of cancer & clinical oncology.

[23]  R. Demicheli,et al.  Estimate of tumor growth time for breast cancer local recurrences: rapid growth after wake-up? , 1998, Breast Cancer Research and Treatment.

[24]  M. Zelen,et al.  Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. , 1989, The New England journal of medicine.

[25]  H Schipper,et al.  Shifting the cancer paradigm: must we kill to cure? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Spratt,et al.  Rates of Growth of Pulmonary Metastases and Host Survival , 1964, Annals of surgery.

[27]  J. Folkman What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[28]  R. Demicheli,et al.  Re: Dormancy of mammary carcinoma after mastectomy. , 2000, Journal of the National Cancer Institute.

[29]  J. Holland,et al.  Surgical adjuvant chemotherapy. , 1977, Annual review of medicine.

[30]  N Gunduz,et al.  Effect of surgical removal on the growth and kinetics of residual tumor. , 1979, Cancer research.

[31]  S. Koscielny,et al.  Re: Local recurrences following mastectomy: support for the concept of tumor dormancy. , 1994, Journal of the National Cancer Institute.

[32]  J. Uhr,et al.  Cancer dormancy: studies of the murine BCL1 lymphoma. , 1991, Cancer research.

[33]  G. Bonadonna,et al.  Salvage treatments in relapsing resectable breast cancer. , 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[34]  R. Nissen-Meyer,et al.  Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer , 1978, Cancer.

[35]  C. Cornelisse,et al.  A prolactin-dependent, metastasising rat mammary carcinoma as a model for endocrine-related tumour dormancy. , 1991, British Journal of Cancer.

[36]  Laird Ak Dynamics of Tumour Growth , 1964 .

[37]  S. Salmon,et al.  Kinetics of tumor growth and regression in IgG multiple myeloma. , 1972, The Journal of clinical investigation.

[38]  G. Hortobagyi,et al.  Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  R. Demicheli,et al.  Proposal for a new model of breast cancer metastatic development. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  F. Grantham,et al.  Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. , 1981, Journal of the National Cancer Institute.

[41]  R Foroni,et al.  An exponential-Gompertzian description of LoVo cell tumor growth from in vivo and in vitro data. , 1989, Cancer research.

[42]  M E Sobel,et al.  Metastasis suppressor genes. , 1990, Journal of the National Cancer Institute.

[43]  R Demicheli Growth of testicular neoplasm lung metastases: tumor-specific relation between two Gompertzian parameters. , 1980, European journal of cancer.

[44]  Laird Ak DYNAMICS OF TUMOR GROWTH. , 1964 .

[45]  M. Tattersall,et al.  Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. , 1997, European journal of cancer.

[46]  B. Cox Variation in the effectiveness of breast screening by year of follow-up. , 1997, Journal of the National Cancer Institute. Monographs.

[47]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.